Press release – Biofina Diagnostics announces two patents were granted in the U.S. and in Canada, from family “BLADDER CANCER DIAGNOSIS AND/OR PROGNOSIS METHOD”.

Biofina Diagnostics announces that two new patents have been granted in 2015 in the United States and in Canada, both belonging to the patent family “BLADDER CANCER DIAGNOSIS AND/OR PROGNOSIS METHOD”.
In the United States the patent 9,097,715 has been granted by the United States Patent and Trademark Office (USPTO). The Patent Term Adjustment determined by the USPTO is 1,289 days which allows the patent to be in force until December 15th, 2030. In Canada the patent has been granted by the Canadian Intellectual Property Office (CIPO) under application number 2,693,847.
The object of this family of patents relates to a non-invasive bladder cancer diagnosis and/or prognosis method based on the detection and quantification in spontaneous urine of the gene expression of certain genes and/or combinations thereof acting as genetic markers of said disease. Likewise, the use of said genes as bladder cancer diagnosis and/or prognosis genetic markers is an object of the present invention, developed by Fina Biotech in collaboration Dr. Antonio Alcaraz and his team at the Hospital Clinic de Barcelona (Spain). Another object of the patent also relates to a bladder cancer diagnosis and/or prognosis kit based on the use of said genes as genetic markers of the disease.
These new patents strengthen the intellectual property portfolio of Biofina Diagnostics and confirm the company strategic commitment in developing non-invasive diagnostic tools useful for patients, doctors and healthcare providers.